Scarica l'app Stockscreener
9.78
2.79%
-0.25
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
Insider Sell: Francesca Barone Sells Shares of Candel Therapeuti - GuruFocus
Candel Therapeutics CSO Francesca Barone sells $235k in stock By Investing.com - Investing.com Australia
Candel Therapeutics CSO Francesca Barone sells $235k in stock - Investing.com
Form 4 Candel Therapeutics Inc For: 1 July By Investing.com - Investing.com UK
Candel Therapeutics (CADL) CSO executes 23,447-share open-market sale under 10b5-1 plan - Stock Titan
Candel Therapeutics (CADL) CTO sells 7,000 shares in planned trade - Stock Titan
Candel Therapeutics (CADL) director receives fully vested grant of 2,199 stock options - Stock Titan
Candel Therapeutics (CADL) director receives fully vested option award - Stock Titan
Candel Therapeutics (CADL) director receives fully vested 381-option equity grant - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel grants new employee 25,000 stock options at $10.30 - Stock Titan
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics initiates phase 3 lung cancer trial By Investing.com - Investing.com South Africa
Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug - marketscreener.com
Candel Therapeutics initiates phase 3 lung cancer trial - Investing.com
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - The Manila Times
Candel opens global phase 3 AURORA trial in lung cancer - Stock Titan
[144] Candel Therapeutics, Inc. SEC Filing - Stock Titan
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Price to sales forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Enterprise value to EBITDA forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Candel Therapeutics, Inc. Actuals & Estimates (NASDAQ:CADL) - TradingView
Enterprise value to EBITDA forward of Candel Therapeutics, Inc. – BOATS:CADL - TradingView
Enterprise value to EBIT forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Candel Therapeutics, Inc. Actuals & Estimates (BOATS:CADL) - TradingView
Price to earnings forward of Candel Therapeutics, Inc. – BOATS:CADL - TradingView
Enterprise value to revenue forward of Candel Therapeutics, Inc. – BOATS:CADL - TradingView
$Candel Therapeutics (CADL.US)$ [Fireworks]New 52 Week High[Fireworks] 9.75 [Twirl][Twirl][Twirl] - Moomoo
CADL Forecast — Price Target — Prediction for 2027 - TradingView
Candel Therapeutics Designates Mark Sims as CCO - Yahoo Finance
Candel Therapeutics names Mark Sims as chief commercial officer By Investing.com - Investing.com Australia
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer Ahead of Planned BLA Filing - citybiz
Candel Therapeutics names Mark Sims as chief commercial officer - Investing.com
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - The Manila Times
Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 - marketscreener.com
Candel Therapeutics, Inc. Files Form 8-K with SEC Detailing Corporate Information and Emerging Growth Status - Minichart
Candel Therapeutics Stockholders Approve Directors and Auditor - TipRanks
Form 4 Candel Therapeutics Inc For: 24 June By Investing.com - Investing.com South Africa
Candel Therapeutics director granted 32,000 options | CADL Insider Trading - Stock Titan
Director at Candel Therapeutics (NASDAQ: CADL) gets 32,000 options - Stock Titan
Director Joseph Papa receives 32,000 CADL stock options at $9.08 exercise price - Stock Titan
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director PAPA JOSEPH C - Moomoo
Candel Therapeutics (NASDAQ: CADL) director awarded 32,000 options - Stock Titan
Candel Therapeutics (CADL) director gets 32,000 stock options at $9.08 - Stock Titan
Candel Therapeutics (CADL) director granted 32,000 stock options - Stock Titan
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Gaeta Renee - Moomoo
Candel Therapeutics (CADL) grants director 32,000 stock options at $9.08 - Stock Titan
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Nabel Gary J. - Moomoo
Director Diem Nguyen awarded 32,000 Candel Therapeutics (CADL) stock options - Stock Titan
Candel Therapeutics (CADL) stockholders elect directors, ratify KPMG at 2026 meeting - Stock Titan
2.26%
2.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):